Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.

Abstract	When metastatic prostate cancer progresses despite androgen suppression but symptoms do not yet warrant cytotoxic therapy, abiraterone appears to prolong overall survival and to delay the onset of some cancer-related symptoms. But beware of cardiac and hepatic adverse effects that are inadequately documented.
Authors
Journal	Prescrire international (Prescrire Int) Vol. 23 Issue 146 Pg. 40-1 (Feb 2014) ISSN: 1167-7422 [Print] France
PMID	24669383 (Publication Type: Journal Article)
Chemical References	Androgen Antagonists Androstenes Androstenols abiraterone
Topics	Androgen Antagonists (adverse effects) Androstenes Androstenols (adverse effects) Chemical and Drug Induced Liver Injury (etiology) Heart Diseases (chemically induced) Humans Male Neoplasm Metastasis Prostatic Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!